Name: Valrubicin
Price: Inquiry

- Overview
  - Chemotherapy for bladder cancer; semi-synthetic analog of doxorubicin
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Antibiotics
    
    Alternative Name
    
    Pentanoic acid 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl )amino]-a-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester;Antibiotic AD 32;N-Trifluoroacetyladriamycin 14-v
    
    CAS Number
    
    56124-62-0
    
    Molecular Formula
    
    C34H36F3NO13
    
    Molecular Weight
    
    723.64 g/mol
    
    MDL Number
    
    MFCD01939322
    
    Note
    
    There is no hazardous surcharge associated with this product.
    There is no special packaging charge associated with this product.
    
    * For research use only. Not for human or veterinary use
- Reference
  - Steinberg et al (2000). Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. Journal of Urology. 179(1):386.
    Christmann-Franck (2004). Structure-based virtual screening: an application to human topoisomerase II alpha. Journal of Medical Chemistry. 47(27):6840-53.
    McKiernan et al (2006). Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. Journal of Clinical Oncology. 24(19):3075-80.